Previous Close | 4.85 |
Open | 4.83 |
Bid | 5.08 x 800 |
Ask | 5.08 x 2200 |
Day's Range | 4.88 - 5.25 |
52 Week Range | 3.59 - 31.54 |
Volume | |
Avg. Volume | 830,500 |
Market Cap | 195.519M |
Beta (5Y Monthly) | 2.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.00 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for ORMP
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-lik
Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.